Search

Displaying results 521 - 530 of 2507 in total
  1. Drug

    PF-00610355

    go.drugbank.com/drugs/DB11871
    Investigational

    PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.

  2. Drug

    Rose bengal

    go.drugbank.com/drugs/DB11182
    ApprovedInvestigational

    The clinical applications of rose bengal as injectable formulation under the name PV-10 in melanoma, breast cancer and skin conditions such as eczema and psoriasis are being investigated in clinical trials

  3. Drug

    Bremelanotide

    go.drugbank.com/drugs/DB11653
    Approved

    [L9635] Bremelanotide was first described in the literature in 2003 when it was known by the investigational code PT-141.

  4. Drug

    Sodium phosphate, monobasic

    go.drugbank.com/drugs/DB09449
    ApprovedInvestigational

    Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.

    Mixtures: CPD/ADSOL Red Cell Preservation Solution System (PL 2209), CPD/ADSOL Red Cell Preservation Solution System (PL 2209)
  5. Drug

    PT-2385

    go.drugbank.com/drugs/DB16055
    Investigational

    PT-2385 is under investigation in clinical trial NCT03108066 (PT2385 for the Treatment of Von Hippel-lindau Disease-associated Clear Cell Renal Cell Carcinoma).

  6. Drug

    TP-271

    go.drugbank.com/drugs/DB15040
    Investigational

    TP-271 is under investigation in clinical trial NCT02724085 (A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271).

  7. Drug

    Tinlorafenib

    go.drugbank.com/drugs/DB17082
    Investigational

    Tinlorafenib (PF-07284890) is a potent, selective, highly brain-penetrant, small-molecule inhibitor of BRAF V600 mutations.[A253992]

  8. Drug

    PF-03463275

    go.drugbank.com/drugs/DB11993
    Investigational

    PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.

  9. Drug

    Methscopolamine

    go.drugbank.com/drugs/DB11315
    Approved

    Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets...

    Mixtures: Dallergy PE, Allergy DN PE
  10. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been t...

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates